Biotechnology company Ionis Pharmaceuticals Inc (Nasdaq:IONS) announced on Tuesday that it has entered into an expanded licensing agreement with Japan's Otsuka Pharmaceutical Co Ltd for donidalorsen, an investigational RNA-targeted therapy for hereditary angioedema (HAE).
Otsuka gains exclusive commercialisation rights in the Asia-Pacific region, adding to its commercialisation rights in Europe. Ionis retains responsibility for global development and plans a US Food and Drug Administration (FDA) filing this year for independent launch in the United States.
The agreement includes a USD20m upfront payment to Ionis with potential milestone and royalty payments tied to regulatory and sales achievements.
Otsuka's regional expertise and infrastructure aim to deliver donidalorsen to HAE patients across Asia-Pacific.
FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
US FDA approves expanded indication for AbbVie's MAVYRET (glecaprevir/pibrentasvir) in acute HCV
Creo Medical secures FDA clearance for SpydrBlade Flex in US market
Psilera collaborates with Hesperos for PSIL-006 preclinical modelling for frontotemporal dementia
Myosin Therapeutics' MT-125 cleared by US FDA to initiate first-in-human trial in glioblastoma
Ondine's Steriwave proven effective against deadly Mucor fungus
AB Science receives EMA approval to extend Masivet shelf life to four years
Hemispherian's GLIX1 receives positive EU opinion for orphan designation in glioma
Arvinas and Pfizer submit FDA application for vepdegestrant in ESR1-mutated breast cancer
NRx Pharmaceuticals files ANDA for preservative-free IV ketamine
Innovent's IBI363 granted second breakthrough therapy designation in China
Implantica reports positive NICE guidance for RefluxStop procedure in UK hospitals